Novartis Closes $12B Avidity Acquisition
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BASEL, Switzerland – February 27, 2026 Novartis AG has successfully completed its acquisition of Avidity Biosciences, Inc., strengthening its...
SAN DIEGO, Calif., February 26, 2026 Avidity Biosciences, Inc. (Nasdaq: RNA) announced that it will present one oral and...
